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Abstract
The bifunctional enzyme methylenetetrahydrofolate dehydrogenase – cyclohydrolase (FolD) is identified as a potential drug
target in Gram-negative bacteria, in particular the troublesome Pseudomonas aeruginosa. In order to provide a
comprehensive and realistic assessment of the potential of this target for drug discovery we generated a highly efficient
recombinant protein production system and purification protocol, characterized the enzyme, carried out screening of two
commercial compound libraries by differential scanning fluorimetry, developed a high-throughput enzyme assay and
prosecuted a screening campaign against almost 80,000 compounds. The crystal structure of P. aeruginosa FolD was
determined at 2.2 A ˚ resolution and provided a template for an assessment of druggability and for modelling of ligand
complexes as well as for comparisons with the human enzyme. New FolD inhibitors were identified and characterized but
the weak levels of enzyme inhibition suggest that these compounds are not optimal starting points for future development.
Furthermore, the close similarity of the bacterial and human enzyme structures suggest that selective inhibition might be
difficult to attain. In conclusion, although the preliminary biological data indicates that FolD represents a valuable target for
the development of new antibacterial drugs, indeed spurred us to investigate it, our screening results and structural data
suggest that this would be a difficult enzyme to target with respect to developing the appropriate lead molecules required
to underpin a serious drug discovery effort.
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Introduction
The Gram-negative Pseudomonas aeruginosa is a serious nosoco-
mial pathogen, accounting for a significant level of hospital-
acquired infections and is particularly troublesome for burn
victims, immunocompromised and cystic fibrosis patients [1,2].
Two major factors contribute to this health problem. Firstly, the
bacterium can survive moist, low nutrient conditions and therefore
persist in the clinical environment. Secondly, numerous drug
resistant strains of P. aeruginosa, employing the common mecha-
nisms of resistance such as modification of the target, active efflux
and/or decreased uptake of drugs, have emerged [3–6]. The need
for novel antibiotics to tackle, in particular Gram-negative bacteria
such as P. aeruginosa, and drug resistant bacteria in general, has
been well publicized along with the practical difficulties associated
with antibacterial drug development [7,8]. However, there are
now genome sequences available for important pathogens and
increasing knowledge of the mechanism of action of existing drugs.
Data are available on which genes encode essential activities and
we have an improved understanding of what types of molecules
are likely to provide either the drug targets or appropriate lead
compounds [9,10]. It is therefore appropriate and timely to
identify and carefully assess potential targets that might provide a
foundation for the future of antimicrobial research.
One area of bacterial metabolism that has been successfully
targeted by antibacterial drugs is the folate biosynthetic pathway.
The enzymes that synthesize, link and modify tetrahydrofolate
(THF) maintain the cellular levels of important cofactors such as
methenyl-, methylene-, formyl- and unsubstituted THF. These
compounds are essential for the synthesis of thymidine, purines,
glycine, methionine, initiator fMet-tRNA and also in the
metabolism of histidine and serine [11]. Higher eukaryotes obtain
these cofactors mainly through diet, whilst bacteria are able to
synthesize these valuable nutrients. Folate biosynthesis depends on
enzymes such as dihydropteroate synthase and dihydrofolate
reductase and inhibitors of these enzymes are used to treat
microbial infections [12–14]. Inspection of folate metabolism in P.
aeruginosa drew our attention to the bifunctional enzyme methy-
lenetetrahydrofolate dehydrogenase - cyclohydrolase. This enzyme
converts N
5,N
10-methylene-THF to N
10-formyl-THF in a two step
reaction, initially in an NADP
+ or NAD
+ dependant oxidization to
N
5,N
10-methenyl-THF by N
5,N
10-methylenetetrahydrofolate de-
hydrogenase [DH, EC:1.5.1.5] and subsequent hydrolysis to N
10-
formyl-THF by N
5,N
10-methenyltetrahydrofolate cyclohydrolase
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enzyme, folD, has been shown by knock-out studies to be essential
in the Gram-positive Bacillus subtilis, as well as the Gram-negative
Escherichia coli, Francisella novicida, Acinetobacter baylyi, and in P.
aeruginosa itself [15–19].
We first considered a diverse set of criteria that have been
established as key areas with respect to target assessment for early
stage antimicrobial drug discovery [20]. The criteria include
genetic and chemical validation of the target, druggability, the
feasibility of an assay, the potential for toxicity and also for drug
resistance, and the availability of accurate structure information to
guide the development of structure-activity relationships. Our
objective was to elucidate the potential of P. aeruginosa FolD
(PaFolD) as a point of therapeutic intervention and to identify what
further information was necessary to provide a comprehensive
assessment. As mentioned, the folD gene has been shown to be
essential in P. aeruginosa providing genetic validation of the target
[19].
Potent inhibitors of FolD are known, including substrate
analogues, and these provide standard compounds and chemical
information concerning modes of inhibition [21–23]. These
inhibitors display biological activity as antiproliferative agents of
mammalian cells but there is no published evidence of antibac-
terial properties [21]. In mammals it appears that the dehydro-
genase - cyclohydrolase activity is necessary for early development
but that adult tissues are less dependent. A potential mechanism
for resistance that might circumvent FolD inhibition is up
regulation of N
10-formyl-THF biosynthesis as observed in the
protozoan Leishmania major [24]. An enzyme assay for FolD is
available and appeared suitable for conversion into a high-
throughput screening (HTS) format [25]. Active recombinant
material has been prepared and structural data are available for
several FolDs including the human and E. coli enzymes, HsDHCH
and EcFolD respectively, though not for PaFolD itself
[23,26,27,28].
We decided that a thorough assessment of PaFolD as a
therapeutic target required structural and compound screening
data and that this would also support the search for new inhibitors
that might represent useful lead compounds. We describe the
preparation of an efficient recombinant protein production system,
protocols for purification and crystallization. The crystal structure
has been determined allowing for a druggability analysis of the
active site and detailed comparisons with other FolD structures
including that of the human enzyme [26]. Screens of a fragment
library and a collection of bioactive molecules were carried out
using differential scanning fluorimetry (DSF). An appropriate
enzyme assay was developed and then applied in an HTS screen.
Enzyme assay and surface plasmon resonance (SPR) measure-
ments were subsequently used to evaluate and characterize the
hits. The data package allows us to assess the tractability of FolD
for antibacterial drug discovery.
Materials and Methods
Recombinant source of PaFolD
The P. aeruginosa folD gene, encoding the bifunctional N
5,N
10-
methylene tetrahydrofolate dehydrogenase/N
5,N
10-methenyl tet-
rahydrofolate cyclohydrolase, was identified in Swissprot (http://
expasy.org/sprot/ accession number Q9I2U6 and the genome
website (http://www.pseudomonas.com/). The gene (locus tag:
PA1796) was amplified from genomic DNA (American Type
Culture Collection 47085, strain PAO1) with the primers carrying
NdeI and Xho1 restriction sites (bold), respectively: 59- CAT-ATG-
ACC-GCA-CAA-CTG-ATC-39,5 9- CTC-GAG-TCA-GTC-
GTG-CAG-G-39. The PCR product was ligated into pCR-
BluntII-TOPO vector using the Zero Blunt TOPO PCR cloning
kit (Invitrogen). The gene was excised and ligated into a modified
pET15b vector (Novagen) containing a Tobacco Etch Virus (TEV)
protease recognition sequence in place of thrombin (pET15b-
TEV). This results in a product carrying an N-terminal hexa-
histidine tag (His-tag), which is cleavable with TEV protease. The
recombinant plasmid was amplified in XL-1 blue E. coli, and the
gene sequence verified, before being transformed into E. coli BL21
(DE3) for protein production.
Purification of PaFolD
E. coli carrying the P. aeruginosa FolD-pET15BTEV plasmid were
cultured at 37uC with shaking at 200 rev min
21 in auto-induction
media supplemented with 50 mg L
21 carbenicillin for approxi-
mately three hours until an OD600 of 0.8 was reached. The
temperature was then reduced to 21uC followed by expression for
22 hours. Cells were harvested by centrifugation (30 min, 3,500 g,
4uC) prior to re-suspension in lysis buffer (buffer A: 50 mM Tris-
HCl pH 7.5, 250 mM NaCl and 20 mM imidazole) containing
DNAse I (100 mg) and an EDTA-free protease-inhibitor cocktail
tablet (Roche). Cells were lysed using a French press at 16,000 psi.
Insoluble debris was separated by centrifugation (50,000 g,
30 min, 4uC) and the soluble fraction was filtered and loaded
onto a HisTrap HP 5 mL column (GE Healthcare) previously
Figure 1. The reaction catalyzed by FolD. N
5,N
10-methylene-THF is
converted to N
5,N
10-methenyl-THF and subsequently N
10-formyl-THF in
a two-step reaction, initially in an NADP
+ or NAD
+ dependant
oxidization to by N
5,N
10-methylenetetrahydrofolate dehydrogenase
[DH, EC:1.5.1.5] and subsequent hydrolysis by N
5,N
10-methenyltetrahy-
drofolate cyclohydrolase [CH, EC:3.5.4.9].
doi:10.1371/journal.pone.0035973.g001
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2+. The His-tagged protein was eluted with a 0–
1 M imidazole gradient in the same buffer. Histidine-tagged TEV
protease (1 mg per 20 mg FolD) was added and the mixture
dialyzed against 50 mM Tris-HCl pH 7.5 and 250 mM NaCl for
three hours. Passage through a His-Trap column separated
PaFolD from TEV protease, the cleaved His-tag peptide and
uncleaved His-tag PaFolD. The sample of PaFolD was then
applied to a Superdex 200, 26/60 column (GE Healthcare), pre-
equilibrated in buffer A. The protein eluted as a dimer with a
molecular mass of approximately 60 kDa. PaFolD was then
concentrated (10 kDa MWCO Amicon Ultra devices, Millipore)
to 15 mg mL
21. Protein concentration was determined spectro-
photometrically using a theoretical extinction coefficient of
6,150 mol L
21 cm
21 at 280 nm calculated using ProtParam
[29]. The high level of protein purity was confirmed by SDS-
PAGE and matrix-assisted laser desorption ionization-time-of-
flight mass spectrometry.
Preparation of biotinylated PaFolD for SPR
For analysis of compounds using SPR it was necessary to
produce an expression system that provided a protein carrying a
biotinylation acceptor peptide (BAP-tag). This BAP-tag peptide
has the sequence 59 - GLNDIFEAQKIEWHE - 39 and is
specifically biotinylated by the E. coli biotin holoenzyme
synthetase, BirA. The modified PaFolD was then purified as
before. Subsequently 30 mM of BAP-tagged PaFolD was incubated
at 37uC overnight in buffer C (10 mM Tris-HCl pH 7.5, 200 mM
KCl, 5 mM MgCl2, 100 mM d-biotin) containing 500 mM ATP
and 1 mM BirA. The sample was passed through a HisTrap HP
column equilibrated with buffer A to remove BirA. The flow
through was collected and concentrated (Amicon 10 kDa MWCO
spin column) to remove free biotin. The incorporation of biotin
was monitored by MALDI-TOF analysis performed at the
University of Dundee ‘Fingerprints’ Proteomics Facility using an
Applied Biosystems Voyager DE-STR spectrometer. The biotiny-
lated protein was flash frozen at 10 mg mL
21 in 50 mM Tris-
HCl, 250 mM NaCl, 15% glycerol, pH 7.5 and stored at 280uC
until required.
Surface Plasmon Resonance (SPR)
A Biacore T100 instrument (GE Healthcare) was used for all
SPR experiments. Biotinylated PaFolD was diluted 50-fold into a
running buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 5 mM MgCl2, 1 mM DTT, 0.05% Tween 20, 1 mM
NADP
+ and 1% DMSO and injected over a streptavidin chip (GE
Healthcare) at a flow rate of 10 mL min
21 for 10 min to obtain a
density of ,4,000 response units. Compounds DDD55519 and
DDD61461 were injected in duplicates at three-fold concentration
series 136 nM–11 mM at a flow rate 30 mL min
21. Association
was measured for 1 min and dissociation for 20 min. Compounds
DDD32388 and DDD58331 were injected at three-fold concen-
tration series of between 1.23 mM–100 mM at a flow rate
30 mL min
21. Association was measured for 1 min and dissocia-
tion 2 min. Data were referenced from a blank streptavidin surface
and blank injections of buffer. Processing was carried out using
Scrubber 2 software (BioLogic Software, Australia).
Fluorescence-based screening by differential scanning
fluorimetry (DSF)
DSF was used to screen different buffers and concentrations of
cofactor to identify conditions under which the protein displayed
optimum thermal stability [30,31]. It was reasoned that such
conditions would favour crystallization. In addition two compound
libraries, the Maybridge fragment set and the Prestwick collection
of biologically active molecules, were screened after first assessing
the suitability of the method for PaFolD, the optimum buffer and
cofactor conditions and the lowest concentration of protein that
generated a strong signal as previously described for our
laboratory [32]. An Mx3005p RT PCR system (Stratagene) was
used to monitor protein unfolding by the increase in fluorescence
of SYPRO Orange dye (Invitrogen). Briefly, the enzyme was tested
against 1000 compounds from the Maybridge Rule of Three (Ro3)
fragment library and 1120 compounds from the Prestwick
Chemical Library. Assays were carried out in 40 mL volumes
with PaFolD at 4 mM, supplemented with 4 mM NADP
+ in
50 mM Tris-HCl, 250 mM NaCl, pH 7.5 in 96 well RT PCR
plates (Abgene). The compounds, 1 mL dissolved in DMSO, were
incubated with the protein solution for 5 minutes prior to 71 cycles
of 1uC temperature increments starting at 25uC. After each 1uC
increase the sample was excited at 492 nm and fluorescence
emissions recorded at 610 nm. The melting temperatures were
plotted against a reference control sample of DMSO only and
each plate contained two known inhibitors of FolD as quality
control measures (LY354899 and LY374571). Compound con-
centrations varied between 1 mM for the Maybridge library and
between 2 mM and 8 mM for the Prestwick library (compounds at
1m gm L
21) with a requirement to limit the concentration of
DMSO to ,2.5% in the final mixture.
Crystallization and data collection
Sitting drop vapour diffusion crystallization trials were carried
out using a Phoenix Liquid Handling System (Art Robins
Instruments/Rigaku) and the JCSG+ MPD, PEG and Classics
screens (Hampton Research). The trials used drops, assembled
from 100 nL of protein solution and an equivalent volume of
reservoir, equilibrated against a 70 mL reservoir at 20uC. Crystals
were observed after three days in conditions with a reservoir of
25% PEG 3350 and 0.2 M magnesium formate. Optimization by
hanging drop (2 mL volume) vapour diffusion gave crystals with
approximate dimensions 0.360.260.1 mm
3. Single crystals were
transferred to a cryo-solution containing the original reservoir
solution supplemented with 40% glycerol prior to flash freezing at
2173uC. Crystals were first characterized in-house with a
Micromax-007 rotating anode generator and R-AXISIV
++ dual
image plate detector (Rigaku), prior to storage in liquid nitrogen.
X-ray diffraction data were then collected at beam line ID29 at the
European Synchrotron Radiation Facility using a wavelength of
0.9814 A ˚. Integration and scaling of data were carried out using
MOSFLM and SCALA [33,34]. The crystals are monoclinic with
space group P21 and unit cell dimensions of a=61.42 A ˚,
b=82.38 A ˚, c=109.90 A ˚, b=94.7u. The molecular weight of a
subunit is 30.7 kDa, and the asymmetric unit consists of four
subunits with a VM value of 2.5 A ˚ 3 Da
21 and solvent content of
approximately 50%.
Structure solution and refinement
The structure was solved by molecular replacement using a
monomer from the EcFolD structure (sequence identity of 67%,
PDB code 1BOA) as the search model [27]. The side chains of the
search model were removed and the rotation and translation
functions (PHASER) positioned four molecules in the asymmetric
unit. Inspection using the graphic software COOT showed that
two homodimers, consistent with the gel filtration results, formed
the asymmetric unit [35,36]. Rigid-body refinement was carried
out in REFMAC5 [37]. Side chains were added to the model
based on inspection of electron and difference density maps,
followed by iterative rounds of restrained refinement, model
Target Assessment of FolD
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lation/Libration/Screw analysis was applied in the latter stages of
the refinement [38]. Model quality was checked using MolProbity
[39]. Structure superpositions were calculated using LSQKAB and
figures were prepared using PyMOL [40,41].
FolD enzyme assay development
Enzyme activity was assayed by measuring the absorbance at
350 nm of the intermediate product in the reaction, N
5,N
10-
methenyl-THF, following acidification of the reaction and
consequent reconversion of the final product formyl-THF to the
intermediate [25]. Following optimization of the assay buffer and
determination of the enzyme linearity, assays were carried out at
room temperature in a 50 mL reaction volume containing 25 mM
bicine, pH 7.9, 1 mM dithiothreitol, 0.05% CHAPS,
0.2 mg mL
21 BSA, 1 nM recombinant FolD, 250 mM NADP
+
and 35 mM N
5,N
10-methylene-THF. Michaelis constants for the
two substrates (NADP
+ and N
5,N
10-methylene-THF) were deter-
mined in an end-point assay, using these buffer and enzyme
conditions.
FolD hit identification
The HTS was performed with a compound collection of 79,029
diverse structures based around 4000 chemical scaffolds. All
compounds were dissolved in 100% DMSO to a concentration of
3 mM. Single point inhibition assays were carried out at room
temperature in clear, flat bottom, polystyrene, 384-well plates
(Matrix). Each assay was performed in a 50 mL reaction volume as
described above. A standard compound (0.5 mL in DMSO) was
transferred to all assay plates using a Cartesian Hummingbird
(Genomics Solutions) before 25 mL of a reaction mix, containing
all assay components except NADP
+ and N
5,N
10-methylene-THF,
was added to assay plates using a Thermo Scientific Well-Mate
(Matrix). The reaction was initiated and stopped with the additions
of 25 mL of substrate and 50 mL of 1 M HCl, respectively, again
using a Well-Mate. The FolD assay was run at room temperature
for 20 min and the signal was allowed to develop for 10 min
before the absorbance of each well was read at 350 nm using an
EnVision multilabel plate reader (PerkinElmer Life Sciences).
ActivityBase (ID Business Solutions) was used for data processing
and analysis.
FolD inhibitor studies
A high hit rate was noted in the primary screen therefore it was
decided to focus on compounds with percentage inhibition values
of 80% or greater for follow up potency testing. Compounds of
interest were cherry picked from the original library plates using a
series of 10-point inhibitor curves (consisting of half-log serial
dilutions of compound in DMSO) and prepared in 384-well plates
using a JANUS workstation (PerkinElmer Life Sciences). Each
compound plate produced 10-point inhibitor curves for 30 test
compounds and two curves for LY374571, the standard
compound in this screen (see following paragraph for inhibitor
details). Following preparation of the inhibitor curves, assays were
carried out as described above. ActivityBase was again used for
data processing and analysis. All IC50 curve fitting was undertaken
within ActivityBase XE utilizing the underlying ‘MATH IQ’
engine of XLfit version 5.1.0.0. A four-parameter logistic dose-
response curve was utilized for compound potency determination.
Compounds for HTS
The substrate, N
5,N
10-methylene-THF, was purchased from
Schirks laboratories, whilst inhibitors LY354899 and LY374571
were synthesised according to previously reported methods [21,23]
and analyzed by NMR, mass spectrometry and high performance
liquid chromatography. All chemicals utilized were of analytical
grade.
Molecular docking
Compounds identified by HTS were positioned into the active
site of the ‘‘open’’ form of PaFolD using the molecular graphics
program COOT. The position of LY354899 bound to the crystal
structure of HsFolD, following least-squares superposition of the
two enzyme structures, provided a suitable template to guide this
modelling. The active site was prepared for docking of the ligand
using ICM Pro (Molsoft) with the centre of the ligand-binding site
defined by a cavity that contained the residues within 5 A ˚ of
LY354899. The top ten docking poses, as scored by ICM Pro,
were subsequently inspected.
Disc diffusion sensitivity testing
Compounds identified by HTS were used in a disc diffusion
sensitivity test against P. aeruginosa. Briefly a single colony of P.
aeruginosa PAO1 ATCC 15692 was used to inoculate a 2 mL
volume of LB media prior to overnight growth at 37uC. The
bacteria were then diluted 1:100 fold prior to 100 mL volumes
plated onto Iso-Sensitest agar plates and dried in air for 5 minutes.
Eight 3 mm discs were impregnated with 5 ml of compound,
dissolved in DMSO, prior to loading onto each plate. Two
controls were used per plate, one a 100% DMSO stock, the other
a1 0mg stock of gentamycin. Six compound dilutions were tested
per plate, ranging from approximately 115 mg to 4.5 ng. Three
compounds with known antifolate activity were tested, namely
methotrexate, LY354899 and LY374571 in addition to the three
singletons, DDD32388, DDD55519 and DDD61461, and two of
the biaryl sulphonamide series that had been identified. Plates
were incubated at 37uC, and zones of inhibition measured after 16
and 48 hours.
Accession number
Coordinates and structure factor data have been deposited with
the PDB, code 4A5O.
Results and Discussion
Structural analysis
An efficient supply of recombinant material, yielding over
30 mg of enzyme per litre of bacterial culture, and an efficient
purification protocol were established. This provided a source of
enzyme for structural studies and a HTS campaign. Ordered
crystals were obtained and the structure of PaFolD, with four
molecules in the asymmetric unit, was solved using a monomer of
EcFolD as the search model for molecular replacement calcula-
tions. PaFolD and EcFolD share 67% sequence identity [27]. The
structure was subsequently refined to 2.2 A ˚ resolution. Crystallo-
graphic statistics are given in Table 1. The four monomers,
labelled A–D, are arranged as two homodimers, consistent with
the observation of dimeric species in size exclusion gel chroma-
tography and with previously determined FolD structures [26–28].
We only detail the A:B dimer (Figure 2) since a least-squares fit of
280 Ca atoms with an RMSD of 0.4 A ˚ indicate that the subunits
are similar, compared to between 0.4 and 0.8 for the other subunit
and the electron density is better defined for this pair compared to
the other homodimer. This is reflected in a slightly lower average
thermal or B-factor value of 44 A ˚ 2 for the A:B dimer compared to
73 A ˚ 2 for the C:D combination. In addition a loop, residues 233–
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subunits.
The PaFolD subunit consists of 284 residues arranged as a two
domain structure, each with an a/b fold, connected by two long
helices. The dimer interface is created by interactions involving
residues on a5, a7 and b6 (Figure 2). Detailed comparison of the
PaFolD structure with other FolD structures, in particular EcFolD
indicates that a loop linking b8 and a10 (residues 231–243) is
significantly different and occludes the active site. A least-square fit
of 280 Ca positions gives an overall RMSD of 2.1 A ˚. However, for
13 residues on the loop the RMSD averages to 7.5 A ˚, with the
largest deviation of 16.4 A ˚ occurring for residue 235 (Figure 3).
Omission of this loop for subsequent least-squared fits reduces the
RMSD to 1 A ˚ over 269 Ca positions. Since the recombinant
PaFolD retains catalytic activity we assign the loop conformation
as an artefact of crystallization but which nonetheless indicates a
flexibility likely relevant to the enzyme activity. Our attempts to
soak inhibitors into the PaFolD crystals resulted in either the
crystals breaking up or the structure revealing the same loop
configuration with no density to suggest ligand binding (data not
shown). Attempts to grow crystals of the enzyme in a different
form or by co-crystallization in the presence of ligands and
inhibitors failed to produce diffraction quality crystals. It was
therefore necessary to model an open form of PaFolD. Using
EcFolD and HsFolD structures as a guide, the active site loop was
remodelled to open up that active site. In addition, other loops
(94–113, 37–64, 165–172, 207–226, 230–268) were manipulated
to convert the PaFolD structure to be more similar to FolD/
DHCH ligand structures previously published. It was this model of
PaFolD, with a more open active site that was used for molecular
docking studies.
Table 1. Crystallographic statistics.
Spacegroup P21
Unit cell parameters 61.57 A ˚, 82.43 A ˚, 109.07 A ˚,9 0 u, 94.7u,9 0 u
Resolution range (A ˚)
A 40 - 2.2 (2.32 - 2.2)
Wavelength (A ˚) 0.9814
Number of measurements 200243 (29494)
Number of unique reflections 55263 (8034)
Multiplicity 9.5 (2.6)
Completeness (%) 99.9 (100)
Mean I/sI 3.6 (3.7)
Wilson B (A ˚2)4 1 . 6
Rmerge
B 0.073(0.477)
Rwork
C 0.23
Rfree
D 0.277
RMSD bonds (A ˚) 0.0073
RMSD angles (u) 1.052
Ramachandran (%)
E
Favoured 96.9
Allowed 2.9
Outliers 0.2
Protein residues 1123
Protein atoms total 8501
Overall B (A ˚2) 42.9/44.5/73.1/72.0
Waters 135
Overall B (A ˚2)3 9 . 8
PEG/Glycerol 1/1
Overall B (A ˚2) 40.8/62.9
Dual occupancy residues 53A, 99A, 133A, 235A, 133B
Missing residues 1A, 1C, 1D, 233-241D, 284D
Low occupancy (Chain A) 18, 21, 59, 85, 191
Low occupancy (Chain B) 18, 21, 27, 56, 59, 64, 194, 212, 223
Low occupancy (Chain C) 2, 9, 14, 15, 21, 22, 24, 27, 29, 31, 33, 43, 48, 51, 59, 63, 64, 68, 70, 73, 78, 79, 80, 137, 149, 194, 240,
271
Low occupancy (Chain D) 9, 18, 22, 23, 25, 27, 29, 31, 33, 54, 56, 59, 61, 63, 64, 118, 138, 194, 212, 217, 223, 247, 251, 252, 275,
282
(A) Values in parentheses refer to the highest resolution bin of 2.32 - 2.2 A ˚ (B). Rmerge=ShSi||(h,i)2,I(h).ShSi I(h,i)( C) Rwork=Shkl||Fo|2|Fc||/S|Fo|, where Fo is the
observed structure factor and Fc the calculated structure factor (D). Rfree is the same as Rwork except calculated using 5% of the data that are not included in any
refinement calculations (E) Ramachandran analysis from MOLPROBITY [44].
doi:10.1371/journal.pone.0035973.t001
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ordered cavity, typically with pronounced hydrophobic character,
able to bind small bioavailable molecules with high affinity [42].
The active site of dihydrofolate reductase (DHFR), an archetypal
target for treatment of cancer and microbial infections, would be
described as druggable. The volume of the DHFR active site is
estimated as 380 A ˚ 3 when calculated from Protein Data Bank
(PDB) codes 2X9G and 3CL9 [43]. Based on crystal structures of
FolD, including that reported here, we estimate the active site to
occupy a volume of approximately 430 A ˚ 3. This is only a modest
increase on DHFR and with some parts of the active site
displaying hydrophobic character (discussed shortly) then the
active site of FolD would be considered well suited to bind drug-
like molecules. Indeed such inhibitors of human FolD have been
identified supporting the conclusion that the active site is indeed
druggable [23]. These inhibitors were primarily developed for
their potential as anticancer agents since the folate pathway
produces essential co-factors for cell division.
Comparison of PaFolD and HsFolD
Since the bifunctional enzyme activity of FolD is present in the
pathogen of interest and in humans it may become an important
selection criteria that inhibitors display specificity against PaFolD
over HsFolD. Now, having determined the structure of PaFolD we
can compare the two structures and consider the likelihood of
selective inhibition. The bacterial and human enzymes share 44%
identity. The least-squares superposition of the HsFolD structure
in complex with cofactor and an inhibitor, and the newly
remodelled PaFolD gives an RMSD of 1.26 A ˚ for 276 Ca atoms.
The NADP
+ binding site is mainly formed by the C-terminal
domain, which displays a Rossmann-fold typical of the small
dehydrogenase/reductase (SDR) family. Previously it has been
noted that FolD carries an YxxxK motif commonly observed in
the SDR family of enzymes and in PaFolD this involves Tyr50 and
Lys54. However in the SDR family, the lysine is involved in
positioning the nicotinamide by virtue of binding the ribose moiety
and the tyrosine provides a hydroxyl group to participate directly
in catalysis [44,45]. In FolD neither residue is in contact with the
cofactor so their contribution to the enzyme activity has to be
different. The tyrosine likely forms van der Waals interactions with
the substrate to hold it in place and we note the hydroxyl group,
positioned to bind solvent, could, in an alternative rotamer,
approach the site where the cyclohydrolase reaction occurs [23]. A
role for the lysine is to act as a general acid base during the
cyclohydrolase reaction [46]. Two other residues are of note,
Gln98 and Asp121, which are conserved in HsFolD as Gln100 and
Asp125 respectively. Roles for this pair of residues have been
assigned on the basis of structural and mutagenesis studies [46].
The glutamine helps to position the side chain of the catalytic
lysine in the active site and the aspartate interacts with and
positions the pterin head group of the substrate (Figure 4).
A number of interactions serve to position the flexible 231–243
loop in the active site. These include a salt bridge formed between
Asp121 and Arg234. Complementary stabilizing associations
involve van der Waals interactions between the side chains of
Tyr50 and Gln235 together with a hydrogen bond donated from
Arg268 NH1 to the carbonyl group of Gln235. These associations
would not be formed in the presence of substrate, which would
directly interact with Asp121 and Tyr50.
The residues identified as being important for catalytic function
are strictly conserved in FolD orthologues. We note however three
non-conservative substitutions in the active site of PaFolD
compared to HsFolD. The residues involved are His53, Asp57
and Arg268 in PaFolD, which in HsFolD correspond to Val55,
Ala59 and Val280 respectively. The side chain of Arg268 is held in
position by a hydrogen bonding interaction formed with Asp57
OD2. Alongside Arg268 is His53. The incorporation of two basic
side chains in place of valines is a significant difference in the
chemical characteristics at one side of the active site of PaFolD
compared to HsFolD. This is noteworthy since it is the type of
difference that might be exploited to engender selectivity into
inhibitors.
Compound screening
In advance of performing a large-scale HTS, PaFolD was
assayed combining DSF with the Prestwick Chemical Library of
drug-like molecules (1,200 compounds) and a bespoke Maybridge
RO3 fragment library of 1,000 compounds. Compounds were
screened at concentrations of 1 mM (Maybridge) or between 2–
8 mM (Prestwick) against 4 mM PaFolD with NADP
+ at a
saturating concentration (4 mM) to block the cofactor-binding
site. The assays were run at a single point aiming to identify
compounds that stabilize the protein. Two standards were
included on each plate, namely the inhibitors 5,6,7,8-tetrahydro-
N
5,N
10-carbonylfolic acid (LY354899) and (2R)-2-[(4-{[(2,5-diami-
no-6-hydroxypyrimidin-4-yl)carbamoyl]amino}phenyl)forma-
mido] pentanedioic acid (LY374571), at 250 mM concentration
[21,23]. The standards gave thermal shifts of +9 and +15uC
respectively (Data not shown). A number of compounds in the
Prestwick library gave apparent thermal shifts of approximately
+10uC, however all of these were rejected due to their intrinsic
fluorescence. None of the remaining compounds gave a shift
greater than +1.5uC. Our experience with DSF is that such small
increases on the melting temperature are insignificant and we
typically do not consider values of less than +2uC as worth follow
up [34]. The lack of hits suggested that a larger, more diverse set of
compounds was required and therefore that it was necessary to
develop a suitable high-throughout assay.
A methylenetetrahydrofolate dehydrogenase assay was adapted
and miniaturized to a 384-well plate format to allow HTS of
79,029 compounds [25]. Enzyme activity was assayed in an
optimised buffer at 1 nM PaFolD. The Michaelis constants (Km)
for the substrate N
5,N
10-methylene-THF and the co-factor NADP
+
Figure 2. Structure of PaFolD. Cartoon representation of a
homodimer of PaFolD with secondary structure labeled. The interface
occurs between a5, a7 and b6 of partner subunits.
doi:10.1371/journal.pone.0035973.g002
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(Figure 5A and 5B). When saturating concentrations of either
substrate or co-factor were required N
5,N
10-methylene-THF was
used at 250 mM and NADP
+ at 1 mM. For screening the
compound library N
5,N
10-methylene-THF was fixed at a concen-
tration of 35 mM and NADP
+ was saturating at 1 mM and the
assay was stopped after 20 minutes (within the linear range of the
assay). The standard compound for the screen was LY374571
which displays IC50 of ,30 nM against PaFolD (Figure 5C),
consistent with a value of 3 nM reported against HsFolD under
slightly different assay conditions [23].
PaFolD was screened against in-house, diverse compound
libraries at 30 mM. Assay robustness and reproducibility and the
overall quality of the screening were assessed by monitoring assay
performance throughout the campaign. The screening data
showed a mean Z9 factor of 0.7960.04 and the mean percent
coefficient of variation was 1.4260.67 [47].
Figure 3. Different loop conformations at the active site. Superposition of a subunit of E.coli FolD (PDB code: 1B0A black) against PaFolD. A
loop in the PaFolD structure (red residues 231–243) adopts a different orientation compared to the EcFolD structure (blue) with equivalent residues
(Gln235 Pa and Leu235 Ec) shifting by as much as 16.7 A ˚ and an angle of nearly 60u. In the orientation seen for the PaFolD structure, the loop sits over
the active site.
doi:10.1371/journal.pone.0035973.g003
Figure 4. Analysis of active site residues. Superposition of the HsDHCH (green) - NADP
+ (yellow) - LY354899 (black) complex (PDB code: 1DIB)
onto the remodeled PaFolD structure (grey). Residues that interact with either NADP
+ or LY354899 molecules in HsDHCH and their counterparts in
PaFolD structure are shown as sticks.
doi:10.1371/journal.pone.0035973.g004
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hits, which necessitated an arbitrary cut-off at 80% inhibition for
retesting in duplicate. Following the retest screen and the exclusion
of compounds identified as potential non-specific inhibitors of
PaFolD, twenty-four active compounds were progressed for
potency testing. For these compounds, duplicate ten-point dose
response curves were generated (ranging from 30 mM to 1 nM).
We observed an excellent correlation between the two replicate
pIC50 determinations, with the linear regression of these data
returning a correlation coefficient of 0.92 (Figure 6). For each
compound, residual material from the potency compound plates
was subjected to LC-MS (liquid chromatography–mass spectrom-
etry) analysis to confirm the molecular structures and sample
purity. Thirteen of these twenty-four compounds were recon-
firmed as active inhibitors of FolD using resupplied material, two
of which proved to be unstable and were therefore excluded from
the study. The remaining eleven compounds were assessed based
on their core chemical structure, with eight of the compounds
being assigned to one hit series of biaryl sulphonamides, and the
remaining three representing unrelated singletons (Figure 7). The
three singletons, DDD32388, DDD55519 and DDD61461, along
with three representatives from the hit series were analysed by
SPR to investigate binding to PaFolD using an alternative platform
(data not shown). The binding of DDD32388 and compounds
from the biaryl sulphonamide hit series was weak and in the case
of at least one of the sulphonamide series, non-specific. Binding of
both DDD55519 and DDD61461 to PaFolD was confirmed with
both compounds exhibiting slow rates of association suggestive of
binding at an allosteric site. The LY374571 inhibitor, a compound
that binds within the FolD active site, could not compete off this
binding. These results are consistent with the Hill coefficient value
of 2.6 obtained for compound DDD61461 (Figure 7) since positive
cooperativity induced by allosteric inhibition within the PaFolD
dimer would result in a coefficient greater than unity. However,
the Hill coefficient of 1.2 for DDD55519 is suggestive of a non-
cooperative interaction.
Having identified DDD32388 and members of the biaryl
sulphonamide as PaFolD inhibitors, attempts were made to obtain
crystal structures of the complexes. In this we were unsuccessful
and so used computational methods to dock the compounds into
the active site of PaFolD. Previous structural analyses of the FolD
active site indicate no gross domain movements associated with
ligand binding [26,27]. There is however a closing down of the
active site when NADP
+ is present and from our study we observe
placement of the 231–243 loop into the substrate-binding site. We
carried out docking studies with DDD32388 as a lead hit using the
‘‘open’’ PaFolD model. The poses with the best scores for both of
the biaryl sulphonamide compounds were inspected and potential
interactions with the protein mapped. Compound DDD32388 is
predicted to adopt a similar conformation to that seen for
LY354899 with the hydrophobic benzyl group stacking against the
Tyr50 side chain and the electronegative chlorine substituent faces
towards, yet is just of range of the basic Arg268 and His53
(Figure 8). The sulphonamide group is predicted to interact with
the side chain of Gln98, whilst the head group of the molecule is
slightly tilted in comparison to LY354899 and makes numerous
interactions through Thr142 and Asp121. Further structural data
would be necessary to accurately determine the binding of these
and other compounds in the active site.
As a follow up to the enzyme inhibition assays we tested for in
vivo efficacy, using P.aeruginosa PAO1 in a disc diffusion sensitivity
assay. Whilst the standard antibacterial compound used, genta-
mycin, cleared a radius of 13 mm, all the other compounds,
including LY354899 and LY374571, failed to give any clearance
Figure 5. FolD assay development. (A) N
5,N
10-methylene-THF Km
determination in the presence of 1 mM NADP
+.( B)N A D P
+ KM
determination in the presence of 1 mM N
5,N
10-methylene-THF. All KM
measurement data are presented as mean 6 SD (n=4) (C) Represen-
tative IC50 determination for LY374571. Data points are mean 6 SD
(n=14). This representative example returns an IC50 for LY374571 of
2763 nM.
doi:10.1371/journal.pone.0035973.g005
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are highly potent inhibitors of PaFolD they are not active against
the bacteria and this is likely a consequence of poor uptake.
This observation raises a serious point and presents a significant
challenge to this project. In order to address issues of uptake by
Gram-bacteria and to design chemical modifications that influence
pharmacokinetics it would be best to have an understanding of the
structure activity relationships of the new inhibitors. This lack of
information, due to difficulties in obtaining structural data on
PaFolD with the ligands, is severely limiting. Note that the new
inhibitors that have been found are much less potent than the
standard compounds and so there would be a requirement to
enhance binding capabilities in addition to addressing issues of
bioavailability.
Concluding remarks
We prioritized the bifunctional PaFolD as a potential Gram-
negative antibacterial target following consideration of genetic and
metabolic data and set out to assess the potential value of this
enzyme for drug discovery. The crystal structure was determined
and compared with that of the human enzyme. The active site is
assessed as possessing the right combination of properties in terms
of size, and juxtaposition of hydrophilic and hydrophobic
components to warrant being described as druggable. Moreover,
structural differences between the bacterial and human enzymes
suggest it may be possible to discriminate between the enzyme of
pathogen and host. A compound screening campaign was carried
out, following the development of the appropriate assay condi-
tions, against PaFolD. Three singleton compounds and one hit
series (eight compounds) were confirmed as inhibiting FolD using
repurchased material and an orthogonal screening platform (SPR)
was subsequently used to confirm the binding of these compounds
to PaFolD. Models for several of the inhibitors binding the enzyme
were constructed by computational methods. None of these hit
compounds showed potencies comparable to the previously
characterised folate-analogue FolD inhibitors. However, the
recalcitrant nature of the enzyme to crystallize in an open form
or a form suitable for the soaking with known ligands or identified
fragments posed our biggest challenge. Future work will focus on
identifying a surrogate FolD that will provide structural data to
confirm the mode of binding of these compounds and also the
current ligands. It may actually be beneficial to work with the
human enzyme simply on the basis that there is precedent for
getting crystal structures of enzyme-ligand complexes.
Taking the results together, it is clear that although the
biological and structural data suggest PaFolD is an excellent target
for therapeutic intervention the screening data suggest that it is in
Figure 6. Replicate testing. Correlation between replicate pIC50 values for each of the 24 compounds advanced to potency testing. Linear
regression of these data returned a correlation coefficient of 0.92.
doi:10.1371/journal.pone.0035973.g006
Figure 7. Confirmed hit compounds from hit discovery
campaign. Summary of the compounds and series identified through
the HTS and their respective potencies and Hill slope values.
doi:10.1371/journal.pone.0035973.g007
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are of low potency and it is difficult to derive a clear structure-
function relationship to support the process whereby inhibition
might be improved. One strategy to address this issue could be by
adopting a medicinal chemistry approach to synthesise and assay
different compound series. However, we caution that known,
potent FolD inhibitors have no effect when tested directly on
bacteria. We would be wary of carrying out further work that
drives up potency against FolD but that still leaves us with
compounds that have no antibacterial activity. A striking example
of how similar difficulties have compromised antibacterial drug
research is given by the huge effort employed by GlaxoSmithKline
between 1995 and 2001. Only sixteen of sixty-seven HTS
campaigns on antibacterial targets resulted in the identification
of hit compounds and only five of these hits resulted in lead
compound identification [7]. Despite difficulties the development
of novel antibacterial compounds remains an urgent and
immediate need highlighting the importance of ongoing efforts
in this challenging area of drug discovery.
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